Treponema Pallidum InfectionMATCH-POINTNCT07290439
Improving Maternal and Child Health Through Point-of-care STI Testing
A study testing Point-of-care STI tests in people with Treponema Pallidum Infection and Chlamydia Trachomatis Infection, run by Emory University at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection
- What is being tested?
- Point-of-care STI tests
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 756 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Aug 2026to Jun 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Pregnant and clinically indicated for STI testing (syphilis and/or Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV) at a prenatal care (PNC ) or labor and delivery (L\&D) triage visit at Grady Memorial Hospital (GMH). Indications for STI testing in pregnancy at GMH:
- Syphilis, CT, NG, and TV indicated at first PNC visit
- Syphilis serologic testing additionally indicated in 3rd trimester and at delivery
- CT/NG/TV additionally indicated in the 3rd trimester for those <25 or with increased risk [1]
- Additional testing recommended based on clinical signs or symptoms (e.g., genital lesion or vaginal discharge, new exposure history)
- English or Spanish-speaking
Show all 19Show fewer
- If <16 years of age, has a parent or legal guardian present
- Have STI risk factor:
- <25 years of age
- Reports current substance use
- Reported or documented history of a positive STI
- More than one current sex partner
- A current sex partner who has concurrent partners
- A new sex partner (<6 months )
- A current sex partner who has an STI
- Exchange of sex for money or drugs
- Incarceration
- No previous prenatal care during the current pregnancy
- Able to follow study procedures and provide written informed consent or assent, as appropriate
Who cannot join
- Indicated for syphilis test: negative RPR test during this pregnancy
- Indicated for syphilis test: ever had a previous syphilis diagnosis (lifetime history)
- Indicated for CT/NG/TV test: negative for all three of CT, NG, and TV within the previous 1 month
- Indicated for CT/NG/TV test: positive for any of CT, NG, and/or TV and completed treatment <3 weeks prior
- Stakeholders:
- GMH PNC or L\&D providers, GMH leadership, Georgia Dept of Health leadership
- >=18 years of age
- Able to follow study procedures and provide verbal informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Kimberly Workowski, MD contact
United States1 site, 1 recruiting
- Recruiting
Grady Memorial Hospital
Atlanta, Georgia, 30303
Kimberly Workowski, MD, 404-686-7893, kworkow@emory.edu
Kimberly Workowski, MD
About this study
Official title: Improving Maternal and Child Health Through Point-of-care STI Testing (MATCH-POINT)
The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. It will also learn about the feasibility, acceptability, and cost-effectiveness of implementing POCTs in a large safety-net hospital setting.
The main questions it aims to answer are:
Read more
- Do POCTs reduce delays in STI treatment compared with standard laboratory-based testing?
- What barriers, facilitators, and processes affect POCT implementation in prenatal and obstetric care?
- What are the costs and cost-effectiveness of POCTs compared with standard testing?
Participants will:
- Complete a baseline survey and receive either POCTs (fingerstick blood draw or vaginal swab) or standard laboratory STI testing.
- If diagnosed with an STI, complete a follow-up survey approximately one month later.
- Stakeholders (providers, hospital leadership, and public health officials) will complete interviews to inform implementation strategies.
Read the detailed description
Sexually transmitted infections (STIs) represent a growing public health crisis in the United States, with disproportionate impact among Black women and women residing in the Southeastern region. National surveillance data demonstrate alarming increases in syphilis, with reported cases rising by 937% and congenital syphilis cases increasing by 755% over the past decade. In pregnant women, untreated or delayed treatment of STIs is associated with severe adverse reproductive outcomes, including stillbirth, preterm birth, and vertical transmission to the infant.
At Grady Memorial Hospital (GMH), a large safety-net hospital in Atlanta, Georgia, the current standard of care for syphilis diagnosis relies on rapid plasma reagin (RPR) screening, confirmatory treponemal testing, and patient history. This process requires patient recontact for counseling, treatment initiation, and partner notification. Similarly, testing for chlamydia (CT), gonorrhea (NG), and trichomonas (TV) is performed using laboratory-based nucleic acid amplification tests (NAATs), which typically require 1-3 days for results. The absence of same-day diagnostic results creates significant barriers to timely treatment, as recontacting patients is often challenging, and transportation or socioeconomic constraints may limit access to care.
STI counseling and treatment at GMH are provided by the clinical team in accordance with the Centers for Disease Control and Prevention (CDC) STI Treatment Guidelines. Recommended regimens include intramuscular benzathine penicillin G (single dose for early syphilis; three weekly doses for latent or unknown duration syphilis), oral azithromycin for chlamydia in pregnancy, intramuscular ceftriaxone for gonorrhea, and a one-week course of oral metronidazole for trichomonas. Patients with positive results are retested per GMH standard of care, consistent with CDC recommendations.
Despite adherence to national guidelines, treatment delays remain common among pregnant women presenting to GMH's outpatient prenatal care (PNC) clinic and Labor \& Delivery (L\&D) triage. These delays increase risk of onward transmission, including mother-to-child transmission, and contribute to adverse reproductive outcomes.
To address these challenges, multidisciplinary experts in obstetrics, infectious diseases, clinical trials, and implementation science at Emory University have developed the MATCH-POINT study. This study will evaluate the effectiveness and scalability of point-of-care tests (POCTs) for syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women receiving care at GMH. GMH serves a predominantly under-resourced patient population with high STI prevalence and elevated maternal and child morbidity and mortality.
Findings from MATCH-POINT will inform strategies for integrating POCTs into routine prenatal and obstetric care, with the goal of reducing treatment delays, improving maternal and infant outcomes, and preventing onward transmission. Results will be shared with key stakeholders, including the Georgia Department of Public Health, to guide recommendations for broader implementation and scalability of POCTs across safety-net hospitals and clinics serving under-resourced pregnant women throughout the Southeastern United States.
- Conditions
- Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
- Being tested
- Point-of-care STI tests, Standard of care STI testing
- Keywords
- Prenatal care, Point of care test
- Medical subject headings
- Syphilis, Gonorrhea, Trichomonas Vaginitis, Sexually Transmitted Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Point-of-care STI testsDiagnostic test
Point-of-care testing for syphilis and/or chlamydia, gonorrhea, and trichomonas, depending on clinical indication at the visit.
Testing will be performed using the Syphilis Health Check (SHC) and/or the Visby Sexual Health Test.
- Syphilis Health Check (SHC)
- Single-use, disposable, fully integrated rapid test.
- Provides results in approximately 10 minutes.
- Detects syphilis antibodies (IgM and IgG to treponemal antigens) from fingerstick, whole blood, serum, or plasma.
- Visby Sexual Health Test (Visby Medical):
- Single-use, disposable, fully integrated rapid PCR-based assay.
- Provides results in <30 minutes.
- Detects Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis from vaginal swabs.
Standard of care STI testingDiagnostic test
Also called SOC
Standard of care for STI testing
Testing procedures:
- Blood samples will be collected for syphilis screening using rapid plasma reagin (RPR) with reflex treponemal testing.
- Vaginal swab samples will be collected for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) testing using nucleic acid amplification tests (NAATs).
| Study group | Role | What they receive |
|---|---|---|
| Control arm | Active comparator | Participants will undergo routine clinical care at Grady Memorial Hospital (GMH), consistent with CDC STI Treatment Guidelines.
* Positive results will be communicated via phone and/or Patient Portal.
* For trichomoniasis or chlamydia, treatment will involve sending a prescription to the patient's preferred pharmacy. For syphilis or gonorrhea, patients will be asked to return to the clinic for an antibiotic infection. Receives: Diagnostic Test: Standard of care STI testing |
| Intervention arm | Experimental | If participants wait for POCT results:
* Positive results will prompt same-day counseling and treatment.
* Treatment will be directly observed for gonorrhea and syphilis, or provided as a same-day prescription for trichomonas.
* Chlamydia treatment may be directly observed or prescribed, depending on the clinical setting, consistent with the standard of care.
If participants do not wait for POCT results:
* Positive results will be communicated via phone and/or Patient Portal.
* Treatment will proceed as in the standard-of-care control arm. Receives: Diagnostic Test: Point-of-care STI tests; Diagnostic Test: Standard of care STI testing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to treatment
Percentage of participants with onset of treatment within 1 week vs in more than a weeks time frame.
Time from STI diagnosis to medication administered (syphilis, NG, and some CT infections) or prescription written (TV and some CT infections)
Measured: Baseline (STI testing), up to pregnancy completion (up to 41 weeks)
Secondary outcomes (9)
Time to STI treatment completion
Time between STI diagnosis and:
- Treatment completion
- Prescriptions being filled
- Partner STI treatment Pregnancy outcomes Follow-up testing Linkage to care
Measured: Baseline (STI diagnosis) and 1 month follow-up
Repeat STI positives
Number of participants testing positive for the same infection documented a second time meeting the following criteria: there was documentation of appropriate treatment between those diagnoses, and there were at least 4 weeks between tests.
Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Stillbirths
The number of stillbirths will be reported. This is defined as fetal death occurring at ≥20 weeks' gestation.
Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Miscarriage
The number of miscarriages will be reported. This is defined as a spontaneous loss of pregnancy before 20 weeks' gestation.
Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Ectopic pregnancy
Number of ectopic pregnancies will be reported. This is defined as implantation of the pregnancy outside the uterine cavity (e.g., fallopian tube, ovary, abdominal cavity).
Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Preterm Birth
Number of preterm births will be reported. This is defined as live birth occurring before 37 completed weeks of gestation.
Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Pre mature rupture of membranes
Number of cases of premature rupture of membranes (PROM) will be reported. This is defined as spontaneous rupture of amniotic membranes before the onset of labor.
Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Chorioamnionitis
Number of cases of chorioamnionitis will be reported. This is defined as intra-amniotic infection characterized by maternal fever plus clinical signs (e.g., uterine tenderness, maternal/fetal tachycardia, purulent amniotic fluid).
Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Postpartum endometritis
Number of cases of postpartum endometritis will be reported. This is defined as infection of the endometrium occurring after delivery, typically presenting with fever, uterine tenderness, and foul-smelling lochia
Measured: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start11 Aug 2026
- Primary completionJun 2029 (estimated)
- Study completionJun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Treponema Pallidum InfectionStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 756 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Minority Health and Health Disparities (NIMHD)
- Responsible party
- Principal investigator, Kristin Wall, Emory University
- Investigators
- Kristin Wall, PhD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07290439
- Sponsor's protocol ID
- 2025P013591
- Other IDs
- R01MD020754
- Acronym
- MATCH-POINT
- Status last verified
- Aug 2026
- First submitted
- 15 Dec 2025
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Minimal, de-identified datasets sufficient to recreate primary analyses will be made publicly available in the repository. The raw data and a data dictionary will be made available in the repository.
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Maternal and Child Health Through Point-of-care STI Testing (MATCH-POINT)
- ClinicalTrials.gov ID
- NCT07290439
- Acronym / sponsor ID
- MATCH-POINT / 2025P013591
- Conditions
- Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
- Keywords
- Prenatal care, Point of care test
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 756 participants (estimated)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- National Institute on Minority Health and Health Disparities (NIMHD)
- Study start
- 11 Aug 2026 (actual)
- Primary completion
- Jun 2029 (estimated)
- Study completion
- Jun 2030 (estimated)
- First posted
- 18 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. It will also learn about the feasibility, acceptability, and cost-effectiveness of implementing POCTs in a large safety-net hospital setting.
The main questions it aims to answer are:
- Do POCTs reduce delays in STI treatment compared with standard laboratory-based testing?
- What barriers, facilitators, and processes affect POCT implementation in prenatal and obstetric care?
- What are the costs and cost-effectiveness of POCTs compared with standard testing?
Participants will:
- Complete a baseline survey and receive either POCTs (fingerstick blood draw or vaginal swab) or standard laboratory STI testing.
- If diagnosed with an STI, complete a follow-up survey approximately one month later.
- Stakeholders (providers, hospital leadership, and public health officials) will complete interviews to inform implementation strategies.
Detailed description
Sexually transmitted infections (STIs) represent a growing public health crisis in the United States, with disproportionate impact among Black women and women residing in the Southeastern region. National surveillance data demonstrate alarming increases in syphilis, with reported cases rising by 937% and congenital syphilis cases increasing by 755% over the past decade. In pregnant women, untreated or delayed treatment of STIs is associated with severe adverse reproductive outcomes, including stillbirth, preterm birth, and vertical transmission to the infant.
At Grady Memorial Hospital (GMH), a large safety-net hospital in Atlanta, Georgia, the current standard of care for syphilis diagnosis relies on rapid plasma reagin (RPR) screening, confirmatory treponemal testing, and patient history. This process requires patient recontact for counseling, treatment initiation, and partner notification. Similarly, testing for chlamydia (CT), gonorrhea (NG), and trichomonas (TV) is performed using laboratory-based nucleic acid amplification tests (NAATs), which typically require 1-3 days for results. The absence of same-day diagnostic results creates significant barriers to timely treatment, as recontacting patients is often challenging, and transportation or socioeconomic constraints may limit access to care.
STI counseling and treatment at GMH are provided by the clinical team in accordance with the Centers for Disease Control and Prevention (CDC) STI Treatment Guidelines. Recommended regimens include intramuscular benzathine penicillin G (single dose for early syphilis; three weekly doses for latent or unknown duration syphilis), oral azithromycin for chlamydia in pregnancy, intramuscular ceftriaxone for gonorrhea, and a one-week course of oral metronidazole for trichomonas. Patients with positive results are retested per GMH standard of care, consistent with CDC recommendations.
Despite adherence to national guidelines, treatment delays remain common among pregnant women presenting to GMH's outpatient prenatal care (PNC) clinic and Labor \& Delivery (L\&D) triage. These delays increase risk of onward transmission, including mother-to-child transmission, and contribute to adverse reproductive outcomes.
To address these challenges, multidisciplinary experts in obstetrics, infectious diseases, clinical trials, and implementation science at Emory University have developed the MATCH-POINT study. This study will evaluate the effectiveness and scalability of point-of-care tests (POCTs) for syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women receiving care at GMH. GMH serves a predominantly under-resourced patient population with high STI prevalence and elevated maternal and child morbidity and mortality.
Findings from MATCH-POINT will inform strategies for integrating POCTs into routine prenatal and obstetric care, with the goal of reducing treatment delays, improving maternal and infant outcomes, and preventing onward transmission. Results will be shared with key stakeholders, including the Georgia Department of Public Health, to guide recommendations for broader implementation and scalability of POCTs across safety-net hospitals and clinics serving under-resourced pregnant women throughout the Southeastern United States.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control arm | Active comparator | Diagnostic Test: Standard of care STI testingParticipants will undergo routine clinical care at Grady Memorial Hospital (GMH), consistent with CDC STI Treatment Guidelines. * Positive results will be communicated via phone and/or Patient Portal. * For trichomoniasis or chlamydia, treatment will involve sending a prescription to the patient's preferred pharmacy. For syphilis or gonorrhea, patients will be asked to return to the clinic for an antibiotic infection. |
| Intervention arm | Experimental | Diagnostic Test: Point-of-care STI tests, Diagnostic Test: Standard of care STI testingIf participants wait for POCT results: * Positive results will prompt same-day counseling and treatment. * Treatment will be directly observed for gonorrhea and syphilis, or provided as a same-day prescription for trichomonas. * Chlamydia treatment may be directly observed or prescribed, depending on the clinical setting, consistent with the standard of care. If participants do not wait for POCT results: * Positive results will be communicated via phone and/or Patient Portal. * Treatment will proceed as in the standard-of-care control arm. |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (19 listed)
- Pregnant and clinically indicated for STI testing (syphilis and/or Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV) at a prenatal care (PNC ) or labor and delivery (L\&D) triage visit at Grady Memorial Hospital (GMH). Indications for STI testing in pregnancy at GMH:
- English or Spanish-speaking
- If <16 years of age, has a parent or legal guardian present
- Have STI risk factor:
- Able to follow study procedures and provide written informed consent or assent, as appropriate
Key exclusion criteria (8 listed)
- Indicated for syphilis test: negative RPR test during this pregnancy
- Indicated for syphilis test: ever had a previous syphilis diagnosis (lifetime history)
- Indicated for CT/NG/TV test: negative for all three of CT, NG, and TV within the previous 1 month
- Indicated for CT/NG/TV test: positive for any of CT, NG, and/or TV and completed treatment <3 weeks prior
- GMH PNC or L\&D providers, GMH leadership, Georgia Dept of Health leadership
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Point-of-care STI testsPoint-of-care testing for syphilis and/or chlamydia, gonorrhea, and trichomonas, depending on clinical indication at the visit. Testing will be performed using the Syphilis Health Check (SHC) and/or the Visby Sexual Health Test. * Syphilis Health Check (SHC) * Single-use, disposable, fully integrated rapid test. * Provides results in approximately 10 minutes. * Detects syphilis antibodies (IgM and IgG to treponemal antigens) from fingerstick, whole blood, serum, or plasma. * Visby Sexual Health Test (Visby Medical): * Single-use, disposable, fully integrated rapid PCR-based assay. * Provides results in <30 minutes. * Detects Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis from vaginal swabs. | Diagnostic test | Intervention arm |
| Standard of care STI testingAlso: SOCStandard of care for STI testing Testing procedures: * Blood samples will be collected for syphilis screening using rapid plasma reagin (RPR) with reflex treponemal testing. * Vaginal swab samples will be collected for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) testing using nucleic acid amplification tests (NAATs). | Diagnostic test | Control arm, Intervention arm |
Primary outcome
Time to treatment
Time frame: Baseline (STI testing), up to pregnancy completion (up to 41 weeks)
Percentage of participants with onset of treatment within 1 week vs in more than a weeks time frame. Time from STI diagnosis to medication administered (syphilis, NG, and some CT infections) or prescription written (TV and some CT infections)
9 secondary outcomes
Time to STI treatment completion
Time frame: Baseline (STI diagnosis) and 1 month follow-up
Repeat STI positives
Time frame: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Stillbirths
Time frame: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Miscarriage
Time frame: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Ectopic pregnancy
Time frame: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Preterm Birth
Time frame: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Pre mature rupture of membranes
Time frame: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Chorioamnionitis
Time frame: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Postpartum endometritis
Time frame: Baseline (STI diagnosis) and up to pregnancy completion (up to 41 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Individual participant dataSharing planned: Yes. Minimal, de-identified datasets sufficient to recreate primary analyses will be made publicly available in the repository. The raw data and a data dictionary will be made available in the repository.
Related trials for Treponema Pallidum Infection
Recruiting
A Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test
HIV1 Infection, HIV 2 Infection
Active, not recruitingPhase 4
Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM
Gonorrhea Male, Chlamydia (Male)
Not yet recruitingPhase 3
Efficacy and Safety of Minocycline Add-on in Patients With Neurosyphilis
Neurosyphilis
Not yet recruiting
Pilot HIV Self-Testing And Self-collected STI Testing Strategy for Sex Worker Empowerment Study
HIV, Syphilis
RecruitingPhase 3
Oral Amoxicillin Compared to Penicillin G Benzathine for the Treatment of Acquired Syphilis.
Syphilis Acquired
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kimberly Workowski, MD contact
Kristin Wall, PhD principal investigator
Emory University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Point-of-care STI tests in people with Treponema Pallidum Infection and Chlamydia Trachomatis Infection, run by Emory University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kristin Wall, PhD ((404)-616-0600, kmwall@emory.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to treatment (time frame: Baseline (STI testing), up to pregnancy completion (up to 41 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.